Induced pluripotent stem cell
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka’s lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent." 
Pluripotent stem cells hold great promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
The most well-known type of pluripotent stem cell is the embryonic stem cell. However, since the generation of embryonic stem cells involves destruction (or at least manipulation)  of the pre-implantation stage embryo, there has been much controversy surrounding their use. Further, because embryonic stem cells can only be derived from embryos, it has so far not been feasible to create patient-matched embryonic stem cell lines.
Since iPSCs can be derived directly from adult tissues, they not only bypass the need for embryos, but can be made in a patient-matched manner, which means that each individual could have their own pluripotent stem cell line. These unlimited supplies of autologous cells could be used to generate transplants without the risk of immune rejection. While the iPSC technology has not yet advanced to a stage where therapeutic transplants have been deemed safe, iPSCs are readily being used in personalized drug discovery efforts and understanding the patient-specific basis of disease.
Depending on the methods used, reprogramming of adult cells to obtain iPSCs may pose significant risks that could limit their use in humans. For example, if viruses are used to genomically alter the cells, the expression of oncogenes (cancer-causing genes) may potentially be triggered. In February 2008, scientists announced the discovery of a technique that could remove oncogenes after the induction of pluripotency, thereby increasing the potential use of iPS cells in human diseases.
- 1 Production
- 1.1 First generation (mouse)
- 1.2 Second generation (mouse)
- 1.3 Human induced pluripotent stem cells
- 1.4 Challenges in reprogramming cells to pluripotency
- 1.5 Alternative approaches
- 1.6 Transcription factors of induction
- 2 Identity
- 3 Safety
- 4 Medical research
- 5 See also
- 6 References
- 7 External links
iPSCs are typically derived by introducing products of specific set of pluripotency-associated genes, or “reprogramming factors”, into a given cell type. The original set of reprogramming factors (also dubbed Yamanaka factors) are the transcription factors Oct4 (Pou5f1), Sox2, cMyc, and Klf4. While this combination is most conventional in producing iPSCs, each of the factors can be functionally replaced by related transcription factors, miRNAs, small molecules, or even non-related genes such as lineage specifiers.
iPSC derivation is typically a slow and inefficient process, taking 1–2 weeks for mouse cells and 3–4 weeks for human cells, with efficiencies around 0.01%–0.1%. However, considerable advances have been made in improving the efficiency and the time it takes to obtain iPSCs. Upon introduction of reprogramming factors, cells begin to form colonies that resemble pluripotent stem cells, which can be isolated based on their morphology, conditions that select for their growth, or through expression of surface markers or reporter genes.
First generation (mouse)
Induced pluripotent stem cells were first generated by Shinya Yamanaka's team at Kyoto University, Japan, in 2006. They hypothesized that genes important to embryonic stem cell (ESC) function might be able to induce an embryonic state in adult cells. They chose twenty-four genes previously identified as important in ESCs and used retroviruses to deliver these genes to mouse fibroblasts. The fibroblasts were engineered so that any cells reactivating the ESC-specific gene, Fbx15, could be isolated using antibiotic selection.
Upon delivery of all twenty-four factors, ESC-like colonies emerged that reactivated the Fbx15 reporter and could propagate indefinitely. To identify the genes necessary for reprogramming, the researchers removed one factor at a time from the pool of twenty-four. By this process, they identified four factors, Oct4, Sox2, cMyc, and Klf4, which were each necessary and together sufficient to generate ESC-like colonies under selection for reactivation of Fbx15.
Similar to ESCs, these iPSCs had unlimited self-renewal and were pluripotent, contributing to lineages from all three germ layers in the context of embryoid bodies, teratomas, and fetal chimeras. However, the molecular makeup of these cells, including gene expression and epigenetic marks, was somewhere between that of a fibroblast and an ESC, and the cells failed to produce viable chimeras when injected into developing embryos.
Second generation (mouse)
In June 2007, three separate research groups, including that of Yamanaka's, a Harvard/University of California, Los Angeles collaboration, and a group at MIT, published studies that substantially improved on the reprogramming approach, giving rise to iPSCs that were indistinguishable from ESCs. Unlike the first generation of iPSCs, these second generation iPSCs produced viable chimeric mice and contributed to the mouse germline, thereby achieving the 'gold standard' for pluripotent stem cells.
These second-generation iPSCs were derived from mouse fibroblasts by retroviral-mediated expression of the same four transcription factors (Oct4, Sox2, cMyc, Klf4). However, instead of using Fbx15 to select for pluripotent cells, the researchers used Nanog, a gene that is functionally important in ESCs. By using this different strategy, the researchers created iPSCs that were functionally identical to ESCs.
Unfortunately, two of the four genes used (namely, c-Myc and KLF4) are oncogenic, and 20% of the chimeric mice developed cancer. In a later study, Yamanaka reported that one can create iPSCs even without c-Myc. The process takes longer and is not as efficient, but the resulting chimeras didn't develop cancer.
Human induced pluripotent stem cells
Generation from human fibroblasts
In November 2007, a milestone was achieved by creating iPSCs from adult human cells; two independent research teams' studies were released – one in Science by James Thomson at University of Wisconsin–Madison and another in Cell by Shinya Yamanaka and colleagues at Kyoto University, Japan. With the same principle used earlier in mouse models, Yamanaka had successfully transformed human fibroblasts into pluripotent stem cells using the same four pivotal genes: Oct3/4, Sox2, Klf4, and c-Myc with a retroviral system. Thomson and colleagues used OCT4, SOX2, NANOG, and a different gene LIN28 using a lentiviral system.
Generation from human renal epithelial cells in urine
On 8 November 2012, researchers from Austria, Hong Kong and China presented a protocol for generating human iPSCs from exfoliated renal epithelial cells present in urine on Nature Protocols. This method of acquiring donor cells is comparatively less invasive and simple. The team reported the induction procedure to take less time, around 2 weeks for the urinary cell culture and 3 to 4 weeks for the reprogramming; and higher yield, up to 4% using retroviral delivery of exogenous factors. Urinary iPSCs (UiPSCs) were found to show good differentiation potential, and thus represent an alternative choice for producing pluripotent cells from normal individuals or patients with genetic diseases, including those affecting the kidney.
Challenges in reprogramming cells to pluripotency
Although the methods pioneered by Yamanaka and others have demonstrated that adult cells can be reprogrammed to iPS cells, there are still challenges associated with this technology:
- Low efficiency: in general, the conversion to iPS cells has been incredibly low. For example, the rate at which somatic cells were reprogrammed into iPS cells in Yamanaka's original mouse study was 0.01–0.1%. The low efficiency rate may reflect the need for precise timing, balance, and absolute levels of expression of the reprogramming genes. It may also suggest a need for rare genetic and/or epigenetic changes in the original somatic cell population or in the prolonged culture. However, recently a path was found for efficient reprogramming which required downregulation of the nucleosome remodeling and deacetylation (NuRD) complex. Overexpression of Mbd3, a subunit of NuRD, inhibits induction of iPSCs. Depletion of Mbd3, on the other hand, improves reprogramming efficiency, that results in deterministic and synchronized iPS cell reprogramming (near 100% efficiency within seven days from mouse and human cells).
- Genomic Insertion: genomic integration of the transcription factors limits the utility of the transcription factor approach because of the risk of mutations being inserted into the target cell’s genome. A common strategy for avoiding genomic insertion has been to use a different vector for input. Plasmids, adenoviruses, and transposon vectors have all been explored, but these often come with the tradeoff of lower throughput.
- Tumors: another main challenge was mentioned above – some of the reprogramming factors are oncogenes that bring on a potential tumor risk. Inactivation or deletion of the tumor suppressor p53, which is the master regulator of cancer, significantly increases reprogramming efficiency. Thus there seems to be a tradeoff between reprogramming efficiency and tumor generation.
- Incomplete reprogramming: reprogramming also faces the challenge of completeness. This is particularly challenging because the genome-wide epigenetic code must be reformatted to that of the target cell type in order to fully reprogram a cell. However, three separate groups were able to find mouse embryonic fibroblast (MEF)-derived iPS cells that could be injected into tetraploid blastocysts and resulted in the live birth of mice derived entirely from iPS cells, thus ending the debate over the equivalence of embryonic stem cells (ESCs) and iPS with regard to pluripotency.
The table at right summarizes the key strategies and techniques used to develop iPS cells over the past half-decade. Rows of similar colors represents studies that used similar strategies for reprogramming.
Mimicking transcription factors with chemicals
One of the main strategies for avoiding problems (1) and (2) has been to use small compounds that can mimic the effects of transcription factors. These molecule compounds can compensate for a reprogramming factor that does not effectively target the genome or fails at reprogramming for another reason; thus they raise reprogramming efficiency. They also avoid the problem of genomic integration, which in some cases contributes to tumor genesis. Key studies using such strategy were conducted in 2008. Melton et al. studied the effects of histone deacetylase (HDAC) inhibitor valproic acid. They found that it increased reprogramming efficiency 100-fold (compared to Yamanaka’s traditional transcription factor method). The researchers proposed that this compound was mimicking the signaling that is usually caused by the transcription factor c-Myc. A similar type of compensation mechanism was proposed to mimic the effects of Sox2. In 2008, Ding et al. used the inhibition of histone methyl transferase (HMT) with BIX-01294 in combination with the activation of calcium channels in the plasma membrane in order to increase reprogramming efficiency. Deng et al. of Beijing University reported on July 2013 that induced pluripotent stem cells can be created without any genetic modification. They used a cocktail of seven small-molecule compounds including DZNep to induce the mouse somatic cells into stem cells which they called CiPS cells with the efficiency – at 0.2% – comparable to those using standard iPSC production techniques. The CiPS cells were introduced into developing mouse embryos and were found to contribute to all major cells types, proving its pluripotency.
Ding et al. demonstrated an alternative to transcription factor reprogramming through the use of drug-like chemicals. By studying the MET (mesenchymal-epithelial transition) process in which fibroblasts are pushed to a stem-cell like state, Ding’s group identified two chemicals – ALK5 inhibitor SB431412 and MEK (mitogen-activated protein kinase) inhibitor PD0325901 – which was found to increase the efficiency of the classical genetic method by 100 fold. Adding a third compound known to be involved in the cell survival pathway, Thiazovivin further increases the efficiency by 200 fold. Using the combination of these three compounds also decreased the reprogramming process of the human fibroblasts from four weeks to two weeks. 
In April 2009, it was demonstrated that generation of iPS cells is possible without any genetic alteration of the adult cell: a repeated treatment of the cells with certain proteins channeled into the cells via poly-arginine anchors was sufficient to induce pluripotency. The acronym given for those iPSCs is piPSCs (protein-induced pluripotent stem cells).
In 2008, Hochedlinger et al. used an adenovirus to transport the requisite four transcription factors into the DNA of skin and liver cells of mice, resulting in cells identical to ESCs. The adenovirus is unique from other vectors like viruses and retroviruses because it does not incorporate any of its own genes into the targeted host and avoids the potential for insertional mutagenesis. In 2009, Freed et al. demonstrated successful reprogramming of human fibroblasts to iPS cells. Another advantage of using adenoviruses is that they only need to present for a brief amount of time in order for effective reprogramming to take place.
Also in 2008, Yamanaka et al. found that they could transfer the four necessary genes with a plasmid. The Yamanaka group successfully reprogrammed mouse cells by transfection with two plasmid constructs carrying the reprogramming factors; the first plasmid expressed c-Myc, while the second expressed the other three factors (Oct4, Klf4, and Sox2). Although the plasmid methods avoid viruses, they still require cancer-promoting genes to accomplish reprogramming. The other main issue with these methods is that they tend to be much less efficient compared to retroviral methods. Furthermore, transfected plasmids have been shown to integrate into the host genome and therefore they still pose the risk of insertional mutagenesis. Because non-retroviral approaches have demonstrated such low efficiency levels, researchers have attempted to effectively rescue the technique with what is known as the PiggyBac Transposon System. The lifecycle of this system is shown below. Several studies have demonstrated that this system can effectively deliver the key reprogramming factors without leaving any footprint mutations in the host cell genome. As demonstrated in the figure, the piggyBac transposon system involves the re-excision of exogenous genes, which eliminates issues like insertional mutagenesis
Stimulus-triggered acquisition of pluripotency cell
In January 2014, two articles were published claiming that a type of pluripotent stem cell can be generated by subjecting the cells to certain types of stress (bacterial toxin, a low pH of 5.7, or physical squeezing); the resulting cells were called STAP cells, for stimulus-triggered acquisition of pluripotency.
In light of difficulties that other labs had replicating the results of the surprising study, in March 2014, one of the co-authors has called for the articles to be retracted. On 4 June 2014, the lead author, Obokata agreed to retract both the papers  after she was found to have committed ‘research misconduct’ as concluded in an investigation by RIKEN on 1 April 2014.
Studies by Blelloch et al. in 2009 demonstrated that expression of ES cell-specific microRNA molecules (such as miR-291, miR-294 and miR-295) enhances the efficiency of induced pluripotency by acting downstream of c-Myc . More recently (in April 2011), Morrisey et al. demonstrated another method using microRNA that improved the efficiency of reprogramming to a rate similar to that demonstrated by Ding. MicroRNAs are short RNA molecules that bind to complementary sequences on messenger RNA and block expression of a gene. Morrisey’s team worked on microRNAs in lung development, and hypothesized that their microRNAs perhaps blocked expression of repressors of Yamanaka’s four transcription factors. Possible mechanisms by which microRNAs can induce reprogramming even in the absence of added exogenous transcription factors, and how variations in microRNA expression of iPS cells can predict their differentiation potential discussed by Xichen Bao et al.
Transcription factors of induction
The generation of iPS cells is crucially dependent on the transcription factors used for the induction.
Oct-3/4 and certain products of the Sox gene family (Sox1, Sox2, Sox3, and Sox15) have been identified as crucial transcriptional regulators involved in the induction process whose absence makes induction impossible. Additional genes, however, including certain members of the Klf family (Klf1, Klf2, Klf4, and Klf5), the Myc family (c-myc, L-myc, and N-myc), Nanog, and LIN28, have been identified to increase the induction efficiency.
- Oct-3/4 (Pou5f1) Oct-3/4 is one of the family of octamer ("Oct") transcription factors, and plays a crucial role in maintaining pluripotency. The absence of Oct-3/4 in Oct-3/4+ cells, such as blastomeres and embryonic stem cells, leads to spontaneous trophoblast differentiation, and presence of Oct-3/4 thus gives rise to the pluripotency and differentiation potential of embryonic stem cells. Various other genes in the "Oct" family, including Oct-3/4's close relatives, Oct1 and Oct6, fail to elicit induction, thus demonstrating the exclusiveness of Oct-3/4 to the induction process.
- Sox family: The Sox family of transcription factors is associated with maintaining pluripotency similar to Oct-3/4, although it is associated with multipotent and unipotent stem cells in contrast with Oct-3/4, which is exclusively expressed in pluripotent stem cells. While Sox2 was the initial gene used for induction by Yamanaka et al., Jaenisch et al., and Thomson et al., other transcription factors in the Sox family have been found to work as well in the induction process. Sox1 yields iPS cells with a similar efficiency as Sox2, and genes Sox3, Sox15, and Sox18 also generate iPS cells, although with decreased efficiency.
- Klf family: Klf4 of the Klf family of transcription factors was initially identified by Yamanaka et al. and confirmed by Jaenisch et al. as a factor for the generation of mouse iPS cells and was demonstrated by Yamanaka et al. as a factor for generation of human iPS cells. However, Thomson et al. reported that Klf4 was unnecessary for generation of human iPS cells and in fact failed to generate human iPS cells. Klf2 and Klf4 were found to be factors capable of generating iPS cells, and related genes Klf1 and Klf5 did as well, although with reduced efficiency.
- Myc family: The Myc family of transcription factors are proto-oncogenes implicated in cancer. Yamanaka et al. and Jaenisch et al. demonstrated that c-myc is a factor implicated in the generation of mouse iPS cells and Yamanaka et al. demonstrated it was a factor implicated in the generation of human iPS cells. However, Thomson et al., Yamanaka et al. Usage of the "myc" family of genes in induction of iPS cells is troubling for the eventuality of iPS cells as clinical therapies, as 25% of mice transplanted with c-myc-induced iPS cells developed lethal teratomas. N-myc and L-myc have been identified to induce instead of c-myc with similar efficiency.
- Nanog: In embryonic stem cells, Nanog, along with Oct-3/4 and Sox2, is necessary in promoting pluripotency. Therefore, it was surprising when Yamanaka et al. reported that Nanog was unnecessary for induction although Thomson et al. has reported it is possible to generate iPS cells with Nanog as one of the factors.
- LIN28: LIN28 is an mRNA binding protein expressed in embryonic stem cells and embryonic carcinoma cells associated with differentiation and proliferation. Thomson et al. demonstrated it is a factor in iPSC generation, although it is unnecessary.
- Glis1: Glis1 is transcription factor that can be used with Oct-3/4, Sox2 and Klf4 to induce pluripotency. It poses numerous advantages when used instead of C-myc.
Induced pluripotent stem cells are similar to natural pluripotent stem cells, such as embryonic stem (ES) cells, in many aspects, such as the expression of certain stem cell genes and proteins, chromatin methylation patterns, doubling time, embryoid body formation, teratoma formation, viable chimera formation, and potency and differentiability, but the full extent of their relation to natural pluripotent stem cells is still being assessed.
Gene expression and genome-wide H3K4me3 and H3K27me3 were found to be extremely similar between ES and iPS cells. The generated iPSCs were remarkably similar to naturally isolated pluripotent stem cells (such as mouse and human embryonic stem cells, mESCs and hESCs, respectively) in the following respects, thus confirming the identity, authenticity, and pluripotency of iPSCs to naturally isolated pluripotent stem cells:
- Cellular biological properties
- Morphology: iPSCs were morphologically similar to ESCs. Each cell had round shape, large nucleolus and scant cytoplasm. Colonies of iPSCs were also similar to that of ESCs. Human iPSCs formed sharp-edged, flat, tightly packed colonies similar to hESCs and mouse iPSCs formed the colonies similar to mESCs, less flat and more aggregated colonies than that of hESCs.
- Growth properties: Doubling time and mitotic activity are cornerstones of ESCs, as stem cells must self-renew as part of their definition. iPSCs were mitotically active, actively self-renewing, proliferating, and dividing at a rate equal to ESCs.
- Stem cell markers: iPSCs expressed cell surface antigenic markers expressed on ESCs. Human iPSCs expressed the markers specific to hESC, including SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, TRA-2-49/6E, and Nanog. Mouse iPSCs expressed SSEA-1 but not SSEA-3 nor SSEA-4, similarly to mESCs.
- Stem Cell Genes: iPSCs expressed genes expressed in undifferentiated ESCs, including Oct-3/4, Sox2, Nanog, GDF3, REX1, FGF4, ESG1, DPPA2, DPPA4, and hTERT.
- Telomerase activity: Telomerases are necessary to sustain cell division unrestricted by the Hayflick limit of ~50 cell divisions. hESCs express high telomerase activity to sustain self-renewal and proliferation, and iPSCs also demonstrate high telomerase activity and express hTERT (human telomerase reverse transcriptase), a necessary component in the telomerase protein complex.
- Pluripotency: iPSCs were capable of differentiation in a fashion similar to ESCs into fully differentiated tissues.
- Neural differentiation: iPSCs were differentiated into neurons, expressing βIII-tubulin, tyrosine hydroxylase, AADC, DAT, ChAT, LMX1B, and MAP2. The presence of catecholamine-associated enzymes may indicate that iPSCs, like hESCs, may be differentiable into dopaminergic neurons. Stem cell-associated genes were downregulated after differentiation.
- Cardiac differentiation: iPSCs were differentiated into cardiomyocytes that spontaneously began beating. Cardiomyocytes expressed TnTc, MEF2C, MYL2A, MYHCβ, and NKX2.5. Stem cell-associated genes were downregulated after differentiation.
- Teratoma formation: iPSCs injected into immunodeficient mice spontaneously formed teratomas after nine weeks. Teratomas are tumors of multiple lineages containing tissue derived from the three germ layers endoderm, mesoderm and ectoderm; this is unlike other tumors, which typically are of only one cell type. Teratoma formation is a landmark test for pluripotency.
- Embryoid body: hESCs in culture spontaneously form ball-like embryo-like structures termed "embryoid bodies", which consist of a core of mitotically active and differentiating hESCs and a periphery of fully differentiated cells from all three germ layers. iPSCs also form embryoid bodies and have peripheral differentiated cells.
- Chimeric mice: hESCs naturally reside within the inner cell mass (embryoblast) of blastocysts, and in the embryoblast, differentiate into the embryo while the blastocyst’s shell (trophoblast) differentiates into extraembryonic tissues. The hollow trophoblast is unable to form a living embryo, and thus it is necessary for the embryonic stem cells within the embryoblast to differentiate and form the embryo. iPSCs were injected by micropipette into a trophoblast, and the blastocyst was transferred to recipient females. Chimeric living mouse pups were created: mice with iPSC derivatives incorporated all across their bodies with 10%–90% chimerism.
- Tetraploid complementation: iPS cells from mouse fetal fibroblasts injected into tetraploid blastocysts (which themselves can only form extra-embryonic tissues) can form whole, non-chimeric, fertile mice, although with low success rate.
- Epigenetic reprogramming
- Promoter demethylation: Methylation is the transfer of a methyl group to a DNA base, typically the transfer of a methyl group to a cytosine molecule in a CpG site (adjacent cytosine/guanine sequence). Widespread methylation of a gene interferes with expression by preventing the activity of expression proteins, or by recruiting enzymes that interfere with expression. Thus, methylation of a gene effectively silences it by preventing transcription. Promoters of pluripotency-associated genes, including Oct-3/4, Rex1, and Nanog, were demethylated in iPSCs, demonstrating their promoter activity and the active promotion and expression of pluripotency-associated genes in iPSCs.
- DNA methylation globally: Human iPS cells are highly similar to ES cells in their patterns of which cytosines are methylated, more than to any other cell type. However, on the order of a thousand sites show differences in several iPS cell lines. Half of these resemble the somatic cell line the iPS cells were derived from, the rest are iPSC-specific. Tens of regions which are megabases in size have also been found where iPS cells are not reprogrammed to the ES cell state.
- Histone demethylation: Histones are compacting proteins that are structurally localized to DNA sequences that can affect their activity through various chromatin-related modifications. H3 histones associated with Oct-3/4, Sox2, and Nanog were demethylated, indicating the expression of Oct-3/4, Sox2, and Nanog.
- The major concern with the potential clinical application of iPSCs is their propensity to form tumors. Much the same as ESC, iPSCs readily form teratoma when injected into immunodeficient mice. Teratoma formation is considered a major obstacle to stem-cell based regenerative medicine by the FDA.
- A more recent study on motor functional recovery after spinal cord injuries in mice showed that after human-induced pluripotent stem cells were transplanted into the mice, the cells differentiated into three neural lineages in the spinal cord. The cells stimulated regrowth of the damaged spinal cord, maintained myelination, and formed synapses. These positive outcomes were observed for over 112 days after the spinal cord injury, without tumor formation. Nevertheless, a follow-up study by the same group showed distinct clones of human-induced pluripotent stem cells eventually formed tumors.
- Since iPSCs can only be produced with high efficiency at this time using modifications, they are generally predicted to be less safe and more tumorigenic than hESC. All the genes that have been shown to promote iPSC formation have also been linked to cancer in one way or another. Some of the genes are known oncogenes, including the members of the Myc family. While omitting Myc allows for IPSC formation, the efficiency is reduced up to 100 fold.
- A non-genetic method of producing iPSCs has been demonstrated using recombinant proteins, but its efficiency was quite low. However, refinements to this methodology yielding higher efficiency may lead to production of safer iPSCs. Other approaches such as using adenovirus or plasmids are generally thought to be safer than retroviral methods.
- An important area for future studies in the iPSC field is directly testing iPSC tumorigenicity using methods that mimic the approaches that would be used for regenerative medicine therapies. Such studies are crucial since iPSCs not only form teratoma, but also mice derived from iPSCs have a high incidence of death from malignant cancer. A 2010 paper was published in the journal Stem Cells indicating that iPS cells are far more tumorigenic than ESC, supporting the notion that iPS cell safety is a serious concern.
- Concern regarding the immunogenicity of IPS cells arose in 2011 when Zhou et al. performed a study involving a teratomaformation assay and demonstrated that IPS cells produced an immune response strong enough to cause rejection of the cells. When a similar procedure was performed on genetically equivalent ES cells however, Zhou et al. found teratomas, which indicated that the cells were tolerated by the immune system. In 2013, Araki et al. attempted to reproduce the conclusion obtained by Zhou et al. using a different procedure. They took cells from a chimera that had been grown from IPSC clones and a mouse embryo, this tissue was then transplanted into syngenic mice. They conducted a similar trial using ES cells instead of IPSC clone and compared the results. Findings indicate that there was no significant difference in the immunogenic response produced by the IPS cells and the ES cells. Furthermore, Araki et al. reported little or no immunogenic response for both cell lines. Thus, Araki et al. was unable to come to the same conclusion as Zhou et al.
Recent achievements and future tasks for safe iPSC-based cell therapy are collected in the review of Okano et al.
The task of producing iPS cells continues to be challenging due to the six problems mentioned above. A key tradeoff to overcome is that between efficiency and genomic integration. Most methods that do not rely on the integration of transgenes are inefficient, while those that do rely on the integration of transgenes face the problems of incomplete reprogramming and tumor genesis, although a vast number of techniques and methods have been attempted. Another large set of strategies is to perform a proteomic characterization of iPS cells. The Wu group at Stanford University has made significant progress with this strategy. Further studies and new strategies should generate optimal solutions to the five main challenges. One approach might attempt to combine the positive attributes of these strategies into an ultimately effective technique for reprogramming cells to iPS cells.
Another approach is the use of iPS cells derived from patients to identify therapeutic drugs able to rescue a phenotype. For instance, iPS cell lines derived from patients affected by ectodermal dysplasia syndrome (EEC), in which the p63 gene is mutated, display abnormal epithelial commitment that could be partially rescued by a small compound
Disease modeling and drug development
An attractive feature of human iPS cells is the ability to derive them from adult patients to study the cellular basis of human disease. Since iPS cells are self-renewing and pluripotent, they represent a theoretically unlimited source of patient-derived cells which can be turned into any type of cell in the body. This is particularly important because many other types of human cells derived from patients tend to stop growing after a few passages in laboratory culture. iPS cells have been generated for a wide variety of human genetic diseases, including common disorders such as Down syndrome and polycystic kidney disease. In many instances, the patient-derived iPS cells exhibit cellular defects not observed in iPS cells from healthy patients, providing insight into the pathophysiology of the disease. An international collaborated project, StemBANCC, was formed in 2012 to build a collection of iPS cell lines for drug screening for a variety of disease. Managed by the University of Oxford, the effort pooled funds and resources from 10 pharmaceutical companies and 23 universities. The goal is to generate a library of 1,500 iPS cell lines which will be used in early drug testing by providing a simulated human disease environment. Furthermore, combining hiPSC technology and genetically-encoded voltage and calcium indicators provided a large-scale and high-throughput platform for cardiovascular drug safety screening.
A proof-of-concept of using induced pluripotent stem cells (iPSCs) to generate human organ for transplantation was reported by researchers from Japan. Human ‘liver buds’ (iPSC-LBs) were grown from a mixture of three different kinds of stem cells: hepatocytes (for liver function) coaxed from iPSCs; endothelial stem cells (to form lining of blood vessels) from umbilical cord blood; and mesenchymal stem cells (to form connective tissue). This new approach allows different cell types to self-organize into a complex organ, mimicking the process in fetal development. After growing in vitro for a few days, the liver buds were transplanted into mice where the ‘liver’ quickly connected with the host blood vessels and continued to grow. Most importantly, it performed regular liver functions including metabolizing drugs and producing liver-specific proteins. Further studies will monitor the longevity of the transplanted organ in the host body (ability to integrate or avoid rejection) and whether it will transform into tumors. Using this method, cells from one mouse could be used to test 1,000 drug compounds to treat liver disease, and reduce animal use by up to 50,000.
Embryonic cord-blood cells were induced into pluripotent stem cells using plasmid DNA. Using cell surface endothelial/pericytic markers CD31 and CD146, researchers identified 'vascular progenitor', the high-quality, multipotent vascular stem cells. After the iPS cells were injected directly into the vitreous of the damaged retina of mice, the stem cells engrafted into the retina, grew and repaired the vascular vessels.
Labelled iPSCs-derived NSCs injected into laboratory animals with brain lesions were shown to migrate to the lesions and some motor function improvement was observed.
Red blood cells
Although a pint of donated blood contains about two trillion red blood cells and over 107 million blood donations are collected globally, there is still a critical need for blood for transfusion. In 2014, type O red blood cells were synthesized at the Scottish National Blood Transfusion Service from iPSC. The cells were induced to become a mesoderm and then blood cells and then red blood cells. The final step was to make them eject their nuclei and mature properly. Type O can be transfused into all patients. Human clinical trials were not expected to begin before 2016.
The first human clinical trial using autologous iPSCs was approved by the Japan Ministry Health and was to be conducted in 2014 in Kobe. However the trial was suspended after Japan's new regenerative medicine laws came into effect last November. iPSCs derived from skin cells from six patients suffering from wet age-related macular degeneration were to be reprogrammed to differentiate into retinal pigment epithelial (RPE) cells. The cell sheet would be transplanted into the affected retina where the degenerated RPE tissue was excised. Safety and vision restoration monitoring would last one to three years. The benefits of using autologous iPSCs are that there is theoretically no risk of rejection and it eliminates the need to use embryonic stem cells.
- Induced stem cells
- Stem cell treatments
- Stimulus-triggered acquisition of pluripotency cell, a type of pluripotent stem cell that can be generated by immersing cells in an acid
- Induced pluripotent stem cells vs embryonic stem cells lines obtained by SCNT (discussion)
- Takahashi, K; Yamanaka, S (2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors". Cell 126 (4): 663–76. doi:10.1016/j.cell.2006.07.024. PMID 16904174.
- "The Nobel Prize in Physiology or Medicine – 2012 Press Release". Nobel Media AB. 8 October 2012.
- Klimanskaya; et al. (2006). "Human embryonic stem cell lines derived from single blastomeres". Nature (Nature) 444 (7118): 484–485. doi:10.1038/nature05142. PMID 16929302.(subscription required)
- Kaplan, Karen (2009-03-06). "Cancer threat removed from stem cells, scientists say". Los Angeles Times.
- Okita, K; Ichisaka, T; Yamanaka, S (2007). "Generation of germline-competent induced pluripotent stem cells". Nature 448 (7151): 313–7. doi:10.1038/nature05934. PMID 17554338.(subscription required)
- Wernig, M; Meissner, A; Foreman, R; Brambrink, T; Ku, M; Hochedlinger, K; Bernstein, BE; Jaenisch, R (2007). "In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state". Nature 448 (7151): 318–24. doi:10.1038/nature05944. PMID 17554336.
- Maherali N, et al. (2007). "Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution". Cell Stem Cell 1 (1): 55–70. doi:10.1016/j.stem.2007.05.014. PMID 18371336.
- Generations of iPSCs and related references
- Swaminathan, Nikhil (2007-11-30). "Stem Cells – This Time Without the Cancer". Scientific American News. Retrieved 2007-12-11.
- Baker, Monya (2007-12-06). "Adult cells reprogrammed to pluripotency, without tumors". Nature Reports Stem Cells. doi:10.1038/stemcells.2007.124. Retrieved 2007-12-11.
- Kolata, Gina (2007-11-21). "Scientists Bypass Need for Embryo to Get Stem Cells". The New York Times. ISSN 0362-4331. Retrieved 2007-12-11.
- Yu J, Vodyanik MA, et al. (2007). "Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells". Science 318 (5858): 1917–1920. doi:10.1126/science.1151526. PMID 18029452.
- Takahashi K, et al. (2007). "Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors". Cell 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. PMID 18035408.
- Zhou T, Benda C, Dunzinger S, Huang Y, Ho JC, Yang J, Wang Y, Zhang Y, Zhuang Q, Li Y, Bao X, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA (7 November 2012). "Generation of human induced pluripotent stem cells from urine samples". Nature Protocols 7 (12): 2080–2089. doi:10.1038/nprot.2012.115. PMID 23138349. Retrieved 1 December 2012.
- Luo M, et al. "& Tao, W., Lu, Z., Grummt, I. (2013), NuRD Blocks Reprogramming of Mouse Somatic Cells into Pluripotent Stem Cells". STEM CELLS 31: 1278–1286. doi:10.1002/stem.1374.
- Yoach Rais, Asaf Zviran, Shay Geula, et al. (2013) Deterministic direct reprogramming of somatic cells to pluripotency. Nature, doi:10.1038/nature12587
- Selvaraj V, Plane JM, Williams AJ, Deng W (April 2010). "Switching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologies". Trends in Biotechnology 28 (4): 214–23. doi:10.1016/j.tibtech.2010.01.002. PMC 2843790. PMID 20149468.
- Okita, K; Nakagawa, M.; Hyenjong, H.; Ichisaka, T.; Yamanaka, S. (2008). "Generation of mouse induced pluripotent stem cells without viral vectors". Science 322 (5903): 949–953. doi:10.1126/science.1164270. PMID 18845712.
- Stadtfeld, M; Nakagawa, M; Hyenjong, H; Ichisaka, T; Yamanaka, S (2008). "Induced pluripotent stem cells generated without viral integration". Science 322 (5903): 949–53. doi:10.1126/science.1164270. PMID 18845712.
- Woltjen, K; Michael, IP; Mohseni, P; Desai, R; Mileikovsky, M; Hämäläinen, R; Cowling, R; Wang, W; Liu, P (2009). "piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells". Nature 458 (7239): 766–770. doi:10.1038/nature07863. PMID 19252478.
- RM, Mario; Strati, Katerina; Li, Han; Murga, Matilde; Blanco, Raquel; Ortega, Sagrario; Fernandez-Capetillo, Oscar; Serrano, Manuel; Blasco, Maria A. (2009). "A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity". Nature 460 (7259): 1149–1153. doi:10.1038/nature08287. PMID 19668189.
- Zhao, XY; Li, Wei; Lv, Zhuo; Liu, Lei; Tong, Man; Hai, Tang; Hao, Jie; Guo, Chang-Long; Ma, Qing-wen (2009). "iPS cells produce viable mice through tetraploid complementation". Nature 461 (7260): 86–90. doi:10.1038/nature08267. PMID 19672241.
- Huangfu D, Maehr R, Guo W, et al. (2008). "Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds". Nat Biotechnol 26 (7): 795–7. doi:10.1038/nbt1418. PMID 18568017.
- Desponts, Shi; Desponts, Caroline; Do, Jeong Tae; Hahm, Heung Sik; Schöler, Hans R.; Ding, Sheng (November 2008). "Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds". Cell Stem Cell 3 (5): 568–74. doi:10.1016/j.stem.2008.10.004. PMID 18983970.
- Cyranoski, David (18 July 2013). "Stem cells reprogrammed using chemicals alone". Nature. doi:10.1038/nature.2013.13416. Retrieved 22 July 2013.
- Deng, Hongkui; Hou, Pingping; Li, Yanqin; Zhang, Xu; Liu, Chun; Guan, Jingyang; Li, Honggang; Zhao, Ting; Ye, Junqing (18 July 2013). "Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-Molecule Compounds". Science (sciencemag.org) 341: 651–654. doi:10.1126/science.1239278. PMID 23868920.
- "Major Step In Making Better Stem Cells From Adult Tissue". Science Daily. 19 October 2009. Retrieved 30 September 2013.
- Lin, Tongxiang; Ambasudhan, Rajesh; Yuan, Xu; Li, Wenlin; Hilcove, Simon; Abujarour, Ramzey; Lin, Xiangyi; Hahm, Heung Sol; Hao, Ergeng; Hayek, Alberto; Ding, Sheng (2009). "A chemical platform for improved induction of human iPSCs". Nature Methods (Nature) 6: 805–808. doi:10.1038/nmeth.1393.
- Zhou H, Wu S, Joo JY, et al. (May 2009). "Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins". Cell Stem Cell 4 (5): 381–4. doi:10.1016/j.stem.2009.04.005. PMID 19398399. Retrieved April 23, 2009.
- Desponts, Shi; Desponts, Caroline; Do, Jeong Tae; Hahm, Heung Sik; Schöler, Hans R.; Ding, Sheng (2008). "Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds". Cell Stem Cell 3 (5): 568–74. doi:10.1016/j.stem.2008.10.004. PMID 18983970.
- Zhou, Wi; Freed, Curt R. (2009). "Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells". Stem Cells 27 (11): 2667–74. doi:10.1002/stem.201. PMID 19697349.
- Yamanaka, K.; Nakagawa, M.; Hyenjong, H.; Ichisaka, T.; Yamanaka, S. (2008). "Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors". Science 322 (5903): 949–53. doi:10.1126/science.1164270. PMID 18845712.
- David Cyranoski for Nature News. January 29, 2014 Acid bath offers easy path to stem cells
- Tracy Vence for the Scientist. March 11, 2014 Call for STAP Retractions
- Elaine Lies (4 June 2014). "Japan researcher agrees to withdraw disputed stem cell paper". Reuters. Retrieved 4 June 2014.
- Press Release (1 April 2014). "Report on STAP Cell Research Paper Investigation". RIKEN. Retrieved 2 June 2014.
- Judson, RL. "Embryonic stem cell-specific microRNAs promote induced pluripotency". Source the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, California, USA.
- Bao Xichen; Zhu Xihua; Liao Baojian; et al. (Apr 2013). "& Miguel A Esteban (2013) MicroRNAs in somatic cell reprogramming". Current Opinion in Cell Biology 25 (2): 208–214. doi:10.1016/j.ceb.2012.12.004. PMID 23332905.
- Ali, P. S.; Ghoshdastider, U; Hoffmann, J; Brutschy, B; Filipek, S (2012). "Recognition of the let-7g miRNA precursor by human Lin28B". FEBS Letters 586 (22): 3986–90. doi:10.1016/j.febslet.2012.09.034. PMID 23063642.
- Maekawa M, et al. (2011). "Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1". Nature 474 (7350): 225–229. doi:10.1038/nature10106. PMID 21654807.
- Takahashi K, Yamanaka S (August 2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors". Cell 126 (4): 663–76. doi:10.1016/j.cell.2006.07.024. PMID 16904174.
- Guenther, M.G.; Frmapton, G.M.; Soldner, F.; Hockemeyer, D.; Mitalipova, M.; Jaenisch, R.; Young, R.A. (2010). "Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells.". Cell Stem Cell 7 (?): 249–257. doi:10.1016/j.stem.2010.06.015. PMC 3010384. PMID 20682450.
- Zhao, Xiao-Yang; Li, Wei; Lv, Zhuo; Liu, Lei; Tong, Man; Hai, Tang; Hao, Jie; Guo, Chang-Long; Ma, Qing-wen (2009). "iPS cells produce viable mice through tetraploid complementation". Nature 461 (7260): 86–90. doi:10.1038/nature08267. PMID 19672241.
- Kang, Lan; Wang, Jianle; Zhang, Yu; Kou, Zhaohui; Gao, Shaorong (2009). "iPS Cells Can Support Full-Term Development of Tetraploid Blastocyst-Complemented Embryos". Cell Stem Cell 5 (2): 135–138. doi:10.1016/j.stem.2009.07.001. PMID 19631602.
- Michael J. Boland; et al. (2009). "Adult mice generated from induced pluripotent stem cells". Nature 461 (7260): 91–4. doi:10.1038/nature08310. PMID 19672243.
- Lister R, Pelizzola M, Kida YS, Hawkins D, Nery JR, et al. (2011). "Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells". Nature 471 (7336): 68–73. doi:10.1038/nature09798. PMC 3100360. PMID 21289626.
- Knoepfler, Paul S. (2009). "Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative Medicine". Stem Cells 27 (5): 1050–1056. doi:10.1002/stem.37. PMC 2733374. PMID 19415771.
- Satoshi, Nori (2011). "Grafted Human-induced Pluripotent Stem-Cell–Derived Neurospheres Promote Motor Functional Recovery After Spinal Cord Injury In Mice". PNAS 108 (40): 16825–16830. doi:10.1073/pnas.1108077108. PMC 3189018. PMID 21949375.
- Nori, Satoshi; Okada, Yohei; Nishimura, Soraya; Sasaki, Takashi; Itakura, Go; Kobayashi, Yoshiomi; Renault-Mihara, Francois; Shimizu, Atsushi; Koya, Ikuko (2015-10-03). "Long-Term Safety Issues of iPSC-Based Cell Therapy in a Spinal Cord Injury Model: Oncogenic Transformation with Epithelial-Mesenchymal Transition". Stem Cell Reports 4 (3): 360–373. doi:10.1016/j.stemcr.2015.01.006. ISSN 2213-6711. PMC 4375796. PMID 25684226.
- Aoi, T.; Yae, K.; Nakagawa, M.; Ichisaka, T.; Okita, K.; Takahashi, K.; Chiba, T.; Yamanaka, S. (2008). "Generation of Pluripotent Stem Cells from Adult Mouse Liver and Stomach Cells". Science 321 (5889): 699–702. doi:10.1126/science.1154884. PMID 18276851.
- Ivan Gutierrez-Aranda.; et al. (2010). "Human Induced Pluripotent Stem Cells Develop Teratoma More Efficiently and Faster than Human Embryonic Stem Cells Regardless of the Site of Injection". Stem Cells 28 (9): 1568–1570. doi:10.1002/stem.471. PMC 2996086. PMID 20641038.
- Zhao T, Zhang ZN, Rong Z, Xu Y (2011). "Immunogenicity of induced pluripotent stem cells". Nature 474 (7350): 212–5. doi:10.1038/nature10135. PMID 21572395.
- Araki, Ryoko; Mashiro Uda; Yuko Hoki; Misato Sunayama; Miki Nakamura; Shunsuke Ando; Mayumi Sugiura; Hisashi Ideno; Akemi Shimada; Akira Nifuji; Masume Abe (7 February 2013). "Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embroyonic stem cells". Nature 494 (7435): 100–106. doi:10.1038/nature11807. PMID 23302801.
- Okano Hideyuki; Nakamura Masaya; Yoshida Kenji; et al. (Feb 2013). "& Kyoko Miura (2013) Steps Toward Safe Cell Therapy Using Induced Pluripotent Stem Cells". Circulation Research 112: 523–533. doi:10.1161/CIRCRESAHA.111.256149. PMID 23371901.
- Boland, MY; Hazen, Jennifer L.; Nazor, Kristopher L.; Rodriguez, Alberto R.; Gifford, Wesley; Martin, Greg; Kupriyanov, Sergey; Baldwin, Kristin K. (2009). "Adult mice generated from induced pluripotent stem cells". Nature 461 (7260): 91–4. doi:10.1038/nature08310. PMID 19672243.
- Shalom-Feuerstein R et al. Impaired epithelial differentiation of induced pluripotent stem cells from EEC patients is rescued by APR-246/PRIMA-1MET. P.N.A.S. 2012 http://minus.com/lbmC3TVGDx350s
- Park, IH; Arora, N; Huo, H; Maherali, N; Ahfeldt, T; Shimamura, A; Lensch, MW; Cowan, C; Hochedlinger, K; Daley, GQ (Sep 5, 2008). "Disease-specific induced pluripotent stem cells.". Cell 134 (5): 877–86. doi:10.1016/j.cell.2008.07.041. PMC 2633781. PMID 18691744.
- Freedman, BS; Lam, AQ; Sundsbak, JL; Iatrino, R; Su, X; Koon, SJ; Wu, M; Daheron, L; Harris, PC; Zhou, J; Bonventre, JV (October 2013). "Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations.". Journal of the American Society of Nephrology : JASN 24 (10): 1571–86. doi:10.1681/ASN.2012111089. PMID 24009235.
- Grskovic, M; Javaherian, A; Strulovici, B; Daley, GQ (Nov 11, 2011). "Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.". Nature reviews. Drug discovery 10 (12): 915–29. doi:10.1038/nrd3577. PMID 22076509.
- Gerlin, Andrea (5 December 2012). "Roche, Pfizer, Sanofi Plan $72.7 Million Stem-Cell Bank". Bloomberg.com. Retrieved 23 December 2012.
- Shinnawi, Rami; Huber, I; Maizels, L; Shaheen, N; Gepstein, A; Arbel, G; Tijsen, A; Gepstein, L (2015). "Monitoring human-induced pluripotent stem cell-derived cardiomyocytes with genetically encoded calcium and voltage fluorescent reporters.". Stem Cell Reports 5 (4): 582–596. doi:10.1016/j.stemcr.2015.08.009. PMC 4624957. PMID 26372632.
- Baker, Monya (3 July 2013). "Miniature human liver grown in mice". Nature.com. Retrieved 19 July 2013.
- Takebe, Takanori; Sekine, Keisuke; Enomura, Masahiro; Koike, Hiroyuki; Kimura, Masaki; Ogaeri, Takurnori; Zhang, Ran-Ran; Ueno, Yasuharu; Zheng, Yun-Wen (3 July 2013). "Vascularized and functional human liver from an iPSC-derived organ bud transplant". Nature 499: 481–484. doi:10.1038/nature12271.
- Mini-Livers May Reduce Animal Testing
- Mullin, Emily (28 January 2014). "Researchers repair retinas in mice with virus-free stem cells". fiercebiotech.com. Retrieved 17 February 2014.
- Zambidis, Elias; Lutty, Gerard; Park, Tea Soon; Bhutto, Imran; et al. (2014). "Vascular Progenitors From Cord Blood-Derived Induced Pluripotent Stem Cells Possess Augmented Capacity for Regenerating Ischemic Retinal Vasculature". Circulation (American Heart Association) 129 (3): 359–372. doi:10.1161/CIRCULATIONAHA.113.003000.
- Hailiang T, et al. (2013). "Tracking Induced Pluripotent Stem Cells-Derived Neural Stem Cells in the Central Nervous System of Rats and Monkeys". Cellular Reprogramming 15: 435–442.
- "First transfusions of "manufactured" blood planned for 2016". Gizmag.com. Retrieved 2014-04-23.
- Garber, Ken. "RIKEN suspends first clinical trial involving induced pluripotent stem cells". Nature Biotechnology 33 (9): 890–891. doi:10.1038/nbt0915-890.
- Riken Center for Developmental Biology. "Information on p=roposed pilot study of the safety and feasibility of transplantation of autologous hiPSC-derived retinal pigment epithelium (RPE) cell sheets in patients with neovascular age-related macular degeneration". Research. Archived from the original on 26 June 2013. Retrieved 23 July 2013.
- Gallagher, James (19 July 2013). "Pioneering adult stem cell trial approved by Japan". BBC News. Retrieved 23 July 2013.
|Wikimedia Commons has media related to Induced pluripotent stem cells.|
- Center for iPS Cell Research and Application, Kyoto University
- Takahashi, Kazutoshi; Tanabe, Koji; Ohnuki, Mari; Narita, Megumi; Ichisaka, Tomoko; Tomoda, Kiichiro; Yamanaka, Shinya (2007). "Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors". Cell 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. PMID 18035408.
- Takahashi, Kazutoshi; Yamanaka, Shinya (2006). "Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors". Cell 126 (4): 663–676. doi:10.1016/j.cell.2006.07.024. PMID 16904174.
- With few factors, adult cells take on character of embryonic stem cells
- Generating iPS Cells from MEFS through Forced Expression of Sox-2, Oct-4, c-Myc, and Klf4
- 2 Minute Video from BSCRF about Induced Pluripotent Stem Cells
- 20Minute Video / The Discovery and Future of Induced Pluripotent Stem (iPS) Cells by Dr. Yamanaka January 8, 2008
- A blog focusing specifically on iPS cells and research, biotech, and patient-oriented issues
- Fact sheet on reprogramming
- Detailed protocols for reprogramming and for analysis of iPSCs
- University of Oxford practical workshop on pluripotent stem cell technology